Recent

% | $
Quotes you view appear here for quick access.

Exelixis, Inc. Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • erniewerner erniewerner Dec 18, 2012 12:12 PM Flag

    CTC's in mBC

    Interesting article. No discussion though of how drug induced changes in CTC may or may not influence outcome and that is where the emphasis needs to go if one is looking for CTC count as a possible surrogate endpoint. Did mention that baseline CTC was not outcome predictive in patients treated with Avastin. Not sure how to interpret that.

    So far the CTC guys have focussed on that seemingly important 5 cell/7.5 ml count and on 30% reductions in CTC as relevant. I believe those are the endpoints being tested in the Comet trials. Those may or may not be the best measures, but sometimes a compromise plan carried out to completion is better than lengthy searching and optimizing to get the best end result.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • $$$$

      "Did mention that baseline CTC was not outcome predictive in patients treated with Avastin. Not sure how to interpret that."

      Given bevacizumab's noteworthy toxicities in BC, I was driven to consider Wildbiftek's continued benefit vs.toxicity cautions immediately. It's unfortunate that the OncLive interviews are often too skeletal to provide much more than food for thought.

      Each time I find new research into CTC prognostics, I feel reinforced - and compelled to make note, just in case that particular dataset be the straw to break the camel's back. With such a bounty of credible information, separating the wheat from the chaff is a vigil.
      Ernie, you managed to solicit all my daily platitudes...
      GLTA

      • 1 Reply to wilderguide
      • "Given bevacizumab's noteworthy toxicities in BC, I was driven to consider Wildbiftek's continued benefit vs.toxicity cautions immediately." I don't know, it could be good, bad or a little of each. It might be shortening the survival of low CTC patients, lengthening the survival of high CTC patients or a little of each. What it is doing is scrambling predictive value of baseline CTC's

 
EXEL
7.69-0.16(-2.04%)Jun 24 4:00 PMEDT